Skip to content
DataLookout
Menu

EMPA-LIVERNCT07915596

Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

StatusCompleted
PhaseNot specified
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Change in BARD Score
Timeframe: 12 weeks after randomization
Change in liver fat
Timeframe: 24 weeks after randomization

Arms and interventions

Empagliflozin 10 and 15 mg + Standard Therapy

Standard Therapy Alone (Control)

Drugs: Empagliflozin 10/15 mg administered orally once daily in addition to standard treatment for type 2 diabetes mellitus.

Sites

1 site in 1 country

  • Department of MedicineDhaka, Bangladesh